NEWS
Biomed Industries presenting Combination Therapy Protocol of NA-931 and Tirzepatide at ICOCD-2025
December 10, 2024
Biomed Industries Unveils Groundbreaking research on NA-931 as a Potential Treatment for Alcohol Use Disorder
November 25, 2024
Biomed Industries, Inc. presented Phase 1 results of NA-931, an Oral Novel Quadruple Receptor Agonist for Weight Loss at the World Obesity & Weight Management Congress 2024
November 4, 2024
Biomed Industries, Inc. Announces Positive Phase I Results of Oral Quadruple Receptor Agonist NA-931 for Obesity Treatment
October 7, 2024
Biomed Industries, Inc. Unveils Quadruple Receptor Agonist for Remarkable Weight Loss with Minimal Adverse Effects at the 2024 International Obesity Conference
Septemebr 23, 2024
Biomed Industries, Inc. Unveils a New Neurogenesis Hypothesis with Clinical Data for Alzheimer's and Depression Treatment
Septemebr 9, 2024
Alzheimer's Disease and Obesity: Biomed Industries, Inc. Unveils Groundbreaking Link and New Treatment Approach
August 26, 2024
Biomed Industries, Inc. Presents Groundbreaking Research on the Link Between Alzheimer’s Disease and Stroke
August 19, 2024
Biomed Industries, Inc. Presents Phase 3 Clinical Trial Protocol for Combination Therapy for Alzheimer’s Disease
August 5, 2024
Biomed Industries, Inc. to Present Five Pivotal Papers on Alzheimer’s Disease Therapy at AAIC 2024-Philadelphia
July 9, 2024
Biomed Industries, Inc. Presents NA-931 and NA-941 for Treatment of Obesity and MASH at ADA Conference and Global MASLD Congress 2024
July 1, 2024
Biomed Industries, Inc. to Present a New Quadruple Receptor Agonist for Treatment of Obesity at ADA’s 84th Scientific Sessions and Euro Obesity Congress in June 2024
June 11, 2024
Biomed Industries, Inc. Announces Breakthrough Drug for the Treatment and Prevention of Stroke
May 6, 2024
Biomed Industries, Inc. announces the First Triple IGF-1/GLP-1/GIP Receptor Agonist NA-931 for the Treatment of Obesity
March 12, 2024
Biomed Industries Inc. Presented Groundbreaking Research at the AD/PD™ 2024 International Conference
March 5, 2024
Biomed Industries Inc. Seeks Collaboration for New Diabetes/Obesity Drug
February 1, 2024
Biomed Industries Inc. Engages a Leading Global CRO for its Phase 2B Clinical Trial of NA-831
December 19, 2023
Biomed Industries to Present Data on the History of Failure of Anti-Amyloid Drugs for Treatment of Alzheimer's Disease
October 12, 2023
Biomed Industries, Inc. to showcase its research at Clinical Trials on Alzheimer’s Disease Conference 2023 in Boston
October 04, 2023
Biomed Industries Presented Alzheimer’s and Major Depressive Disorder Research at the Neurology World Conference
September 18, 2023
Biomed Industries, Inc. announces results of Phase 1B pilot study for treatment of Major Depressive Disorder
August 15, 2023
Biomed Industries, Inc. presented the Neurogenesis Hypothesis, and Phase 2A Clinical Trials Results of NA-831 at the International Conference on Neurology and Neurological Disorders, June 16-17, 2023 in Rome, ITALY
June 17, 2023
Biomed Industries, Inc. offers to acquire Neoleukin Therapeutics (NASDAQ: NLTX)
May 23, 2023
Biomed Industries Introduced the Neurogenesis Hypothesis, and Presented Results of its Phase 2A Clinical Trials of NA-831 at the AD/PD International Conference 2023 in Sweden
April 1, 2023
Biomed Industries acquired MedAware Systems, Inc.
September 1, 2022
Biomed Industries, Inc.™ Inc. presented clinical results on NA-831™ at the Clinical Trials on Alzheimer's Disease (CTAD) International Conference, November 31 to Devember 2, 2022, San Francisco, California.
November 29-December 2,2022
Biomed Industries, Inc.™ Inc. presented three scientific papers on NA-831™ at the Alzheimer's Association International Conference- July 31- August 4, 2022 in San Diego, California.
July 31-August 4, 2022
For further information about our products, please contact us.
